Cover [Abstract]
Entity Registrant Name
Entity Central Index Key
Document Type
Amendment Flag
Entity Voluntary Filers
Current Fiscal Year End Date
Entity Well Known Seasoned Issuer
Entity Shell Company
Entity Emerging Growth Company
Entity Current Reporting Status
Document Period End Date
Entity Filer Category
Document Fiscal Period Focus
Document Fiscal Year Focus
Entity Common Stock Shares Outstanding
Document Annual Report
Document Transition Report
Document Fin Stmt Error Correction Flag
Entity File Number
Entity Incorporation State Country Code
Entity Address Address Line 1
Entity Address City Or Town
Entity Address State Or Province
Entity Address Postal Zip Code
Auditor Name
Auditor Location
Auditor Firm Id
Security 12b Title
Trading Symbol
Entity Interactive Data Current
Document Shell Company Report
Document Registration Statement
Contact Personnel Email Address
Contact Personnel Name
Document Accounting Standard
Entity Addresses Address Type [Axis]
Business Contact [Member]
Consolidated Statements of Financial Position
Assets
Current assets
Cash
Accounts receivable
Prepaids and other current assets
Total assets
[Assets]
Liabilities and Shareholders' Deficit
Current liabilities
Accounts payable and accrued liabilities
Due to related parties (Note 14)
Financial guarantee liability (Note 16(c))
Convertible debentures (Note 5)
Loans payable (Note 6)
Promissory notes (Note 7)
Warrant liabilities (Notes 9(a) and 9(b))
Total current liabilities
[Current liabilities]
Non-current liabilities
Loans payable (Note 6)
[Non-current liabilities]
Total liabilities
[Liabilities]
Deficit
Equity [abstract]
Common shares (Note 8)
Common shares issuable (Notes 8(d) and 8(j))
Reserves (Note 11)
Accumulated other comprehensive income
Accumulated deficit
Deficit attributable to shareholders
[Equity attributable to owners of parent]
Non-controlling interests (Note 12)
Total deficit
[Equity]
Total liabilities and deficit
[Equity and liabilities]
Consolidated Statements of Loss and Comprehensive Loss
Expenses
Consulting fees
Foreign exchange (gain) loss
General and administrative
Professional fees
Research and development
Wages, salaries and employment expenses
Total expenses
[Operating expense]
Loss from operations
[Profit (loss) from operating activities]
Other income (expenses)
Accretion expense (Notes 5 and 6)
[Accretion expense (Notes 5 and 6)]
Changes in fair values of warrant liabilities (Notes 9(a) and 9(b))
Financial guarantee recovery (expense) (Note 16(c))
Gain on extinguishment/forgiveness of debts (Note 14)
Gain on loan extinguishment (Note 6)
Interest expense
[Interest expense]
Other
Penalties recovery (expense)
Settlements and legal provisions, net (Notes 14, 16(a) and 16(d))
Total other income
[Total other income]
Net loss for the year
[Profit (loss)]
Other comprehensive loss to be reclassified to profit and loss subsequently
Foreign currency translation adjustment of foreign operations
Comprehensive loss for the year
[Comprehensive income]
Net loss attributable to:
Company's shareholders
Non-controlling interests (Note 12)
[Profit (loss), attributable to non-controlling interests]
Net loss
[Net loss]
Company's shareholders
[Comprehensive income, attributable to owners of parent]
Non-controlling interests (Note 12)
[Comprehensive income, attributable to non-controlling interests]
Comprehensive loss
[Comprehensive loss]
Net loss per share, basic and diluted
Weighted average shares outstanding, basic and diluted
Consolidated Statements of Shareholders' Deficit
Statement [Table]
Statement [Line Items]
Components of equity [axis]
Common Shares
[Common Shares]
Accumulated Other Comprehensive Income - Foreign Currency Translation
Common Shares Issuable
Reserves
Deficit
Retained earnings [member]
Total Shareholders Deficit
Non-Controlling Interest
Balance, shares
[Number of shares issued]
Balance, amount
Common shares issued for cash (Notes 8(k), 8(l), 8(m), 8(n) and 8(o)), shares
Common shares issued for cash (Notes 8(k), 8(l), 8(m), 8(n) and 8(o)), amount
Equity component of convertible debentures (Note 5)
Share-based payments (Notes 11 and 14)
Foreign currency translation adjustment of foreign operations
Net loss
Subscriptions received (Notes 8(j) and 12)
Settlement of accounts payable and due to related parties (Notes 8(e), 12 and 14), shares
Settlement of accounts payable and due to related parties (Notes 8(e), 12 and 14), amount
Deferred tax on equity component of convertible debentures
Warrants granted as issue costs for convertible debentures (Notes 5(b), 5(c) and 5(e))
Common shares issued for conversion of debentures (Notes 5(b), 5(c), 5(d), 5(f), 8(f) and 14), shares
Common shares issued for conversion of debentures (Notes 5(b), 5(c), 5(d), 5(f), 8(f) and 14), amount
Common shares returned and cancelled (Note 8(i)), shares
Common shares returned and cancelled (Note 8(i)), amount
Exercise of warrants (Note 8(b)), shares
Exercise of warrants (Note 8(b)), amount
Common shares and warrants issued for conversion of debentures (Notes 5(a), 5(c), 5(d), 8(a) and 14), shares
Common shares and warrants issued for conversion of debentures (Notes 5(a), 5(c), 5(d), 8(a) and 14), amount
Balance, amount
Balance, shares
Consolidated Statements of Cash Flows
Operating activities
Net loss
[Net loss 1]
Adjustments to reconcile net loss to net cash used in operating activities:
Accretion expense (Notes 5 and 6)
[Accretion expense (Notes 5 and 6) 1]
Changes in fair values of warrant liabilities (Notes 9(a) and 9(b))
Financial guarantee liability (Note 16(c))
[Financial guarantee liability (Note 16(c))]
Foreign exchange loss
Gain on extinguishment/forgiveness of debts (Note 14)
Gain on extinguishment of loan
Interest expense
[Adjustments for interest expense]
Penalties recovery
[Penalties recovery]
Settlements and legal provisions, net (Note 16(a))
[Gains (losses) on litigation settlements]
Share-based payments (Notes 11(b), 11(c), 11(d) and 14)
Changes in working capital accounts:
Amounts receivable
Prepaids and other current assets
[Adjustments for decrease (increase) in other current assets]
Accounts payable and accrued liabilities
[Adjustments for increase (decrease) in trade and other payables]
Due to related parties
Net cash used in operating activities
[Cash flows from (used in) operating activities]
Financing activities
Proceeds from convertible debenture, net (Note 5)
Proceeds from exercise of warrants
Proceeds from issuance of common shares and warrants, net (Note 8)
Proceeds from promissory notes (Note 7)
Proceeds from subscriptions received (Notes 8(d), 8(j) and 14)
Proceeds from subscriptions received by MedMelior (Note 11)
Repayment of loans payable (Note 6)
[Repayments of non-current borrowings]
Net cash provided by financing activities
[Cash flows from (used in) financing activities]
Effects of exchange rate changes on cash
Net change in cash
[Increase (decrease) in cash and cash equivalents after effect of exchange rate changes]
Cash - beginning of year
[Cash - beginning of year]
Cash - end of year
Nature of Operations and Going Concern
Nature of Operations and Going Concern
Disclosure of going concern [text block]
Material Accounting Policies
Material Accounting Policies
Disclosure of material accounting policy information [text block]
New Accounting Pronouncements
New Accounting Pronouncements
Disclosure of changes in accounting estimates [text block]
Intangible Assets
Intangible Assets
Disclosure of intangible assets [text block]
Convertible Debentures
Convertible Debenture
Loans Payable
Loans Payable
[Loans Payable]
Promissory Notes
Promissory Notes
[Promissory Notes]
Common Shares
Common Shares
Disclosure of classes of share capital [text block]
Share Purchase Warrants
Share Purchase Warrants
[Share Purchase Warrants]
Compensation Options
Compensation Options
[Compensation Options]
Long-term Incentive Plans
Long-term Incentive Plans
Disclosure of share-based payment arrangements [text block]
Noncontrolling Interests
Non-controlling Interests
Supplemental Cash Flow Disclosures
Supplemental Cash Flow Disclosures
Disclosure of cash flow statement [text block]
Related Party Transactions
Related Party Transactions
Disclosure of transactions between related parties [text block]
Income Tax
Income Tax
Disclosure of income tax [text block]
Commitments and Contingencies
Commitments and Contingenciess
Operating Segment
Operating Segment
Disclosure of entity's operating segments [text block]
Fair Value Measurements
Fair Value Measurements
Disclosure of fair value measurement of assets [text block]
Management of Financial Risk
Management of Financial Risks
Management of Capital
Management of Capital
[Management of Capital]
Events After the Reporting Date
Events After the Reporting Date
Disclosure of events after reporting period [text block]
Basis of Compliance
Basis of Measurement and Presentation
Basis of Consolidation
Use of Estimates and Judgments
Foreign Currency
Financial Instruments
Compound Financial Instruments
Cash and Cash Equivalents
Provisions and Contingent Liabilities
Equity
Share-based payments
Comprehensive Income (Loss)
Income (loss) Per Share
Taxes
Related Party Transactions
Description of accounting policy for transactions with related parties [text block]
Segment Reporting
Schedule of consolidating entities
Schedule of convertible debentures
Schedule of loans payable
Schedule of promissory notes
Schedule of convertible securities
Schedule of continuity of liability-classified warrants
Schedule of liability-classified warrants were outstanding
Schedule of assumption used for fair values of warrant liabilities
Schedule of continuity of liability-classified warrants of MedMelior
Schedule of assumption used for fair values of MedMelior warrant liabilities
Schedule of continuity of equity-classified warrants
Schedule of equity-classified warrants were outstanding
Schedule of assumptions used for fair value of other equity-classified warrants issued
Schedule of compensation options
Schedule of continuity of the company's performance stock units (PSUs)
Schedule of performance stock units Outstanding
Schedule of assumptions used for fair value of share-based payment expense of PSU
Schedule of continuity of the company's share purchase options
Schedule of additional information about share purchase options
Schedule of assumptions used for fair value of share purchase options
Summary of the continuity of MedMelior's share purchase options
Schedule of assumptions used for fair value of share purchase options of MedMelior
Schedule of financial information
Schedule of supplemental cash flow disclosures
Schedule of expected income tax expense
Schedule of components of deferred tax
Schedule of deferred income tax assets and liabilities
Schedule of non-capital income tax losses expire
Schedule of continuity of financial guarantee liability
Schedule of fair value measurements assets and liabilities
Schedule of maturity of company's financial liabilities
Net loss
Accumulated deficit
Cash flows from operating activities
Current liabilities exceeded current assets
Business combinations [axis]
Blife Therapeutics Inc. [Member]
BetterLife Pharma US Inc. [Member]
MedMelior Inc. [Member]
BetterLife Pharma Inc. [Member]
Altum Pharma (Australia) Pty Ltd. [Member]
Altum Pharmaceuticals (HK) Limited [Member]
% of ownership
% of ownership
[% of ownership]
Jurisdiction
Intangible assets impaired carrying value
Insurance contracts [axis]
Convertible Debenture [Member]
Beginning balance
Proceeds from issuances of convertible debentures
Transfer of conversion component to equity
Transaction costs
Accretion and interest
Interest payments
Conversion
Ending balance
Types of customers [axis]
Transactions Costs [Member]
Unsecured convertible debenture
Proceeds from issuances of convertible debentures
[Proceeds from issuances of convertible debentures]
Accretion expense on convertible debentures
Transaction costs
[Transaction costs]
Accrued interest
Principal amount converted into common shares
Principal amount converted into common shares to purchase warrants
Principal amount carrying value of convertible debentures
Principal amount
Convertible debenture accrued interest
Warrants fair value
Warrants
Brokers' fee
Debenture interest rate, percentage
Effective interest rate
Debenture maturity date
Warrants maturity date
Conversion price per share
Warrants exercise price
Classes of financial liabilities [axis]
Convertible Debenture [Member]
BetterLife Loan [Member]
MedMelior Loan [Member]
Loans Payable
[Loans Payable 1]
Loans Payable, Beginning Balance
[Loans Payable, Beginning Balance]
Loan extinguishment
Interest payment
Principal payment
Accretion and interest
[Accretion and interest]
Loans Payable, Ending Balance
[Loans Payable, Ending Balance]
Current Loan Payable
[Current portion of non-current borrowings]
Long-Term Loan Payable
[Non-current portion of non-current borrowings]
Loans payable
[Loans payable]
Categories of related parties [axis]
Canada Emergency Business Account
Through September 2027 [Member]
Through October 15, 2027 [Member]
Gain on extinguishment of loan
[Gain on extinguishment of loan]
Repayment of debt
Accrued interest
Loan agreements amount
Loan agreements, description
Accretion expense
Interest rate
Promissory Notes, Begginning Balance
[Borrowings]
Proceeds from issuances of promissory notes (Notes 7(a) and 7(b))
Interest
Promissory Notes, Ending Balance
Promissory Note Two [Member]
Promissory Note One [Member]
Proceeds from issuances of promissory notes
Interest rate
[Interest rate]
Interest
Defined benefit plans [axis]
December 31, 2023 [Member]
April 30, 2024 [Member]
March 28, 2024 [Member]
February 29, 2024 [Member]
April 2, 2024 [Member]
Number of Special Warrants
Allocated to common share
Allocated To Warrant
Number of common share issued
Number of warrant issued
Allocated common share issued
Non-adjusting events after reporting period [axis]
Measurement [axis]
Private Placement [Member]
Non Brokered Private Placement [Member]
Shelf Prospectus [Member]
Share issue costs totaling
Brokers fee
Other transaction costs
Common shares issued
Subscription proceeds
Common shares price per shares
Proceeds from share purchase warrants
Fair value of warrants issued
Fair value of warrants issued
[Fair value of warrants issued]
Fair value of shares issued
Amounts due to related parties
Gains from extinguishment/forgiveness of debts
Received subscription proceeds
Exercise price
Description of warrants
Issuance of share purchase warrants, shares
Issuance of share purchase warrants, value
Gross proceeds for common shares
Common shares issuance expiry date
Common shares issuance cost of fair value
Common shares issuance cancelled
Warrants Outstanding, Beginning Balance
Granted (Note 9(h))
Warrants Outstanding, Ending Balance
Weighted Average Exercise Price, Beginning Balance
Weighted Average Exercise Price change in fair value
Weighted Average Exercise Price Granted (Note 9(h))
Weighted Average Exercise Price, Ending Balance
Weighted average remaining contractual life Beginning Balance
Weighted average remaining contractual life, granted
Weighted average remaining contractual life, Ending Balance
Liability amount, Beginning Balance
Liability amount, granted (Note 9(h))
Liability amount, Change in fair value
Liability amount, Ending Balance
Number of warrants
Exercise price per share
Expire date
Risk free interest rates
Volatilities
Fair values of common shares
Expected dividends
Expected lives
Exercise prices
Fair values of warrants
Classes of financial assets [axis]
Warrants of MedMelior [Member]
Warrants Outstanding, Beginning Balance
Warrants Outstanding, Granted (Note 12)
Number of Warrants Expire
Warrants Outstanding, Ending Balance
Weighted Average Exercise Price, Beginning Balance
Weighted Average Exercise Price, Granted (Note 12)
Weighted Average Exercise Price Expire
Weighted Average Exercise Price, Ending Balance
Weighted average remaining contractual life Beginning Balance
Weighted average remaining contractual life, granted
Weighted average remaining contractual life, Ending Balance
Liability amount, Beginning Balance
Liability amount, granted (note 12)
Liability amount, Change in fair value
Liability amount, Ending Balance
Risk free interest rates
[Risk free interest rate, share options granted]
Volatilities
[Expected volatility, share options granted]
Market prices of common shares
Expected dividends
[Expected dividend as percentage, share options granted]
Expected lives
[Expected lives]
Exercise prices
[Exercise prices]
Fair values of warrants
[Fair values of warrants]
Categories of financial assets [axis]
Equity-classified warrants [Member]
Warrants Outstanding, Beginning Balance
Granted
Expired
Exercised
Warrants Outstanding, Ending Balance
Weighted Average Exercise Price, Beginning Balance
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Expired
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Ending Balance
Weighted average remaining contractual life Beginning Balance
Weighted average remaining contractual life, granted
Weighted average remaining contractual life, Ending Balance
Supplier finance arrangements [axis]
Transaction One [Member]
Transaction Two [Member]
Transaction Three [Member]
Transaction Four [Member]
Transaction Five [Member]
Transaction Six [Member]
Transaction Seven [Member]
Transaction Eight [Member]
Transaction Nine [Member]
Transaction Ten [Member]
Transaction Eleven [Member]
Transaction Twelve [Member]
Number of warrants outstanding
Exercise Price
Expiry Date
Range [axis]
Minimum [Member]
Equity-classified warrants [Member]
[Equity-classified warrants [Member]]
Maximum [Member]
Risk free interest rates
Volatilities
Fair values of common shares on grant date
Fair values of warrants on grant dates
Expected lives
Exercise prices
Dates of grant
Granted pursuant to acquisition
Number of share purchase warrants
Classes of financial instruments [axis]
Compensation Options [Member]
Outstanding, Beginning
Expired
[Expired]
Outstanding and exercisable, Ending
Weighted Average Exercise Price, Outstanding Beginning
Weighted Average Exercise Price, Expired
[Weighted Average Exercise Price, Expired]
Weighted Average Exercise Price, Outstanding and exercisable, Ending
Weighted Average Remaining Contractual Life (years), Outstanding Beginning
Performance Stock Units [Member]
Outstanding, beginning balance
Granted (Note 14)
Forfeited (Note 14)
Outstanding, ending
Performance Stock Units 1 [Member]
Volume weighted average common shares
Vesting provision on March 31, 2021
Total vesting provisions
Description of Volume weighted average common share price
Dates of grant
[Dates of grant]
Risk free interest rates
[Risk free interest rates]
Volatilities
[Volatilities]
Market prices of common shares on grant date
Expected dividends
[Expected dividends]
Expected lives
[Expected lives 1]
Fair value of PSUs on grant date
Share Purchase Options [member]
Number of options, outstanding, beginning
Number of options, Granted
Number of options, Forfeited/Expired
[Number of options, Forfeited/Expired]
Number of options, outstanding, ending
Weighted average exercise price, outstanding, beginnig
Weighted average exercise price, Granted
Weighted average exercise price, Forfeited/Cancelled
Weighted average exercise price, outstanding, ending
Weighted average remaining contractual life, outstanding, beginning
Weighted average remaining contractual life, outstanding, ending
Options 1 [Member]
Options 2 [Member]
Options 3 [Member]
Options 4 [Member]
Options 5 [Member]
Options 6 [Member]
Number of options, outstanding
Options Exercisable
Vesting Terms
Expiry date
Exercise Price
Dates of grant or valuation
Risk free interest rates
Risk free interest rates, minimum
Risk free interest rates, maximum
Volatilities
Volatilities, minimum
Volatilities, maximum
Fair values of common shares on grant or valuation dates
Fair values of common shares on grant or valuation dates, minimum
Fair values of common shares on grant or valuation dates, maximum
Expected dividends
Expected lives
Expected lives, minimum
Expected lives, maximum
Exercise prices
[Exercise prices 1]
Exercise prices, minimum
Exercise prices, maximum
Fair values of options on grant or valuation dates
Fair values of options on grant or valuation dates, minimum
Fair values of options on grant or valuation dates, maximum
MedMelior [Member]
Number of options, outstanding, beginning
Number of options, Granted
Number of options, Expired
Number of options, outstanding, ending
Weighted average exercise price, outstanding, beginning
Weighted average exercise price, Granted
Weighted average exercise price, Expired
Weighted average exercise price, outstanding, ending
Weighted average remaining contractual life, outstanding, Begginning
Weighted average remaining contractual life, outstanding, ending
Market prices of common shares on grant date
Exercise prices
Fair values of options on grant or valuation dates
Black-Scholes option pricing model [member]
Share-based payments related to share purchase options
Share-based payments related to performance stock units
Performance Stock Units
Unrecognized shares based payment expenses
Non controlling Interests [Member]
Current assets
[Current assets]
Non-current assets
Current liabilities
Non-current liabilities
Net liabilities
Net liabilities attributable to NCI
Revenue
Other comprehensive income (loss)
Total comprehensive loss
Net loss attributable to NCI
Net comprehensive loss attributable to NCI
Cash flows used in operating activities
Cash flows provided by investing activities
Cash flows provided by financing activities
Effects of exchange rate changes on cash
Net (decrease) increase in cash
Dividends paid to NCI during the year
Ownership interest rate
Gross proceed
Common stock, shares Issued
Share purchase warrants
Liability amount, granted (note 13)
Expiry date
Exercise price
Subscription proceeds
Settlement of outstanding compensation
Supplemental disclosures:
Interest paid
Non-cash investing and financing activities:
Common shares issued for settlement of amounts due to related parties and accounts payable
Common shares of MedMelior issued for settlement of amounts due to related parties
Brokers' warrants granted as issue costs for convertible debentures
Common shares and share purchase warrants issued for conversion of debentures and accrued interest
Brokers' warrants granted as share issue costs
Chief Executive Officers [Member]
December, 2023 [Member]
August 2023 [Member]
June 2024 [Member]
March 2024 [Member]
Key Management and Director [Member]
Director and Officers [Member]
Director, Officers And Former Officer [Member]
MedMelior [Member]
[MedMelior [Member]]
Officers And Directors [Member]
Officers compensation
Share-based payments
[Payments for share issue costs]
Accured interest amount
Common Stock Shares Issued
Amounts Due to related party
Interest rate
[Effective interest rate of financial assets reclassified out of available-for-sale financial assets]
Subscription proceeds
Stock options granted during the year
Stock option expired
Convertible debentures
Promissory notes issued
Gain on forgiveness of debts
Settlement and legal provisions expense
Accrued interest
[Interest income on impaired financial assets accrued]
Common shares issued vested
Share purchase warrants
Maturity date
Conversion of convertible debentures into common shares
Accured fees
PSU options granted during the year
Settlement of outstanding compensation
Net loss before taxes
Statutory rate
Expected tax recovery
Foreign tax rate differences
Permanent differences and other
Share-based payments
[Share-based payments]
Change in deferred tax assets not recognized
Income tax expense
Financing fees
Convertible debentures
[Convertible debentures]
Net deferred tax asset (liability)
Biological assets by age [axis]
Hong Kong [Member]
Canada [Member]
Australia [Member]
Intangible assets
Property and equipment
Contingent liability
Financing costs
Capital loss
Total unrecognized deductible temporary differences
Tax loss carryforwards
2045 [Member]
2046 [Member]
2032 [Member]
2034 [Member]
2035 [Member]
2036 [Member]
2037 [Member]
2038 [Member]
2039 [Member]
2040 [Member]
2041 [Member]
2042 [Member]
2043 [Member]
2044 [Member]
Non-capital loss carryforwards
Statutory rate
[Statutory rate]
Financial liabilities, Beginning balance
[Financial liabilities]
Change in carrying value
Financial liabilities, Ending balance
Current financial liabilities
Non-current financial liabilities
Financial liabilities
MedMelior [Member]
Chief Executive Officers [Member]
Olymbec Development Inc. [Member]
GSB [Member]
Contract amount
Amount paid by company
Amount paid in future
Financial liabilities
Issuance of stock options
Claim amount termination of employment
Non-brokered private placements
Settlements and legal provisions, net
Settlement of legal claims
Monthly lease payment
Punitive damages charges
Administrative fees
Outstanding lease
Levels of fair value hierarchy [axis]
Level 2 of fair value hierarchy [member]
Level 3 of fair value hierarchy [member]
Level 1 of fair value hierarchy [member]
Cash
[Cash]
Warrant liabilities
Over 12 Months [Member]
0 - 12 Months [Member]
Accounts payable and accrued liabilities
[Accounts payable and accrued liabilities]
Due to related parties
Financial guarantee liability
Convertible debentures
Loans payable
[Loans payable 1]
Promissory notes
Warrant liabilities
[Warrant liabilities]
Total Cash
Description of currency risk
Interest rate benchmarks [axis]
Nonadjustings Events [Member]
Directors Officers An Employee And An Advisory [Member]
Convertible Debentures Note 5(c) [Member]
Convertible Debentures Note 5(d) [Member]
Convertible Debentures February 2024 [Member]
Convertible Debentures March 2024 [Member]
Advisory [Member]
Non Brokered Private Placement [Member]
Officers and Directors [Member]
Convertible debentures issued
Stock options granted
Conversion of accrued interest
Warrants purchase
Warrants purchase
[Warrants purchase]
Maturity dates
Common shares related to services
Common shares related to services, value
Gross proceeds from stock issued
Warrant exercise price
Expiry dates of warrants